IRIS UniCatt

Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.069
NA - Nord America 2.753
EU - Europa 2.020
SA - Sud America 612
AF - Africa 76
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.539
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.653
SG - Singapore 1.298
CN - Cina 848
BR - Brasile 504
DE - Germania 456
IT - Italia 456
SE - Svezia 282
VN - Vietnam 249
FR - Francia 177
IN - India 167
IE - Irlanda 133
GB - Regno Unito 111
ID - Indonesia 94
UA - Ucraina 92
JP - Giappone 84
HK - Hong Kong 78
FI - Finlandia 69
RU - Federazione Russa 69
AR - Argentina 52
CA - Canada 45
BD - Bangladesh 39
MX - Messico 37
KR - Corea 36
TR - Turchia 35
AT - Austria 30
ES - Italia 27
NL - Olanda 27
ZA - Sudafrica 27
IQ - Iraq 25
BE - Belgio 20
PK - Pakistan 19
PL - Polonia 19
IR - Iran 15
VE - Venezuela 15
SA - Arabia Saudita 13
PH - Filippine 12
EC - Ecuador 11
CL - Cile 10
LT - Lituania 10
MA - Marocco 10
RO - Romania 10
CH - Svizzera 9
CO - Colombia 9
JO - Giordania 9
CI - Costa d'Avorio 8
KE - Kenya 8
EG - Egitto 7
KZ - Kazakistan 7
IL - Israele 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
KG - Kirghizistan 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
HN - Honduras 4
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
JM - Giamaica 3
MY - Malesia 3
OM - Oman 3
AL - Albania 2
AW - Aruba 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
CW - ???statistics.table.value.countryCode.CW??? 2
GR - Grecia 2
HU - Ungheria 2
LK - Sri Lanka 2
PA - Panama 2
PE - Perù 2
QA - Qatar 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TO - Tonga 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 8.539
Salva come PNG Salva come JPEG
Città #
Singapore 682
San Jose 385
Ashburn 316
Chandler 278
Hangzhou 188
Beijing 161
Dublin 129
Rome 107
Hyderabad 106
Hefei 99
Ho Chi Minh City 90
New York 86
Jakarta 80
Hong Kong 74
Tokyo 74
Lauterbourg 68
Los Angeles 66
Wilmington 63
Milan 60
San Mateo 60
The Dalles 55
Hanoi 53
Frankfurt am Main 51
Jacksonville 47
Boston 46
Nanjing 42
Munich 40
São Paulo 40
Moscow 37
Helsinki 36
Kent 32
Cattolica 31
Santa Clara 30
Seoul 30
Princeton 29
Dallas 24
Houston 23
Orem 23
Council Bluffs 22
Zhengzhou 22
Redwood City 20
Dearborn 19
Brussels 17
Buffalo 17
Da Nang 17
Lawrence 17
Seattle 17
Washington 17
Atlanta 16
Fairfield 16
Nanchang 16
Ann Arbor 15
Haiphong 15
Nuremberg 15
St Louis 15
Vienna 15
Bremen 14
Chicago 14
Marseille 14
Mexico City 14
Montreal 14
Phoenix 14
Rio de Janeiro 14
Düsseldorf 13
Izmir 13
Johannesburg 13
Paris 13
Shanghai 13
Bari 12
Brooklyn 12
London 12
Mountain View 12
Woodbridge 12
Denver 11
Toronto 11
Baghdad 10
Guangzhou 10
Porto Alegre 10
Amman 9
Belo Horizonte 9
Boardman 9
Brasília 9
Naples 9
Nürnberg 9
Palermo 9
Poplar 9
Portsmouth 9
Stockholm 9
Abidjan 8
Amsterdam 8
Andover 8
Busto Arsizio 8
Dhaka 8
Lappeenranta 8
Manchester 8
Richardson 8
Salvador 8
Turku 8
Bexley 7
Chennai 7
Totale 4.608
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 521
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 360
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 204
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 196
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 181
Sonographic imaging of urinoma 175
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 170
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer 165
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 158
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 145
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 139
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer 138
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 137
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 130
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 120
Recent progress in the use of pharmacotherapy for endometrial cancer 117
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 116
PARP Inhibitors Resistance: Mechanisms and Perspectives 115
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 115
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 114
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 113
Endometrial carcinosarcoma 112
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer 112
Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis 112
Advanced and recurrent endometrial cancer: State of the art and future perspectives 110
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 106
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 106
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 105
A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study 105
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 105
A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms 105
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer 104
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 103
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 103
Sonographic imaging of urinoma. 101
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 101
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? 100
The role of artificial intelligence in managing multimorbidity and cancer 98
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 97
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 97
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 95
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases 95
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 94
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 94
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 93
Newly diagnosed ovarian cancer: Which first-line treatment? 92
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease 91
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC 90
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 89
Clear cell carcinoma of the endometrium 88
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 88
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial 88
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 86
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 85
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma 84
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 83
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 82
Diagnosis of uterine leiomyosarcoma 5 years after magnetic-resonance-guided high-intensity focused ultrasound treatment of fibroid 82
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 82
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 81
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 79
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 77
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 76
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 75
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 75
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 73
Dostarlimab: From preclinical investigation to drug approval and future directions 71
Management of stage III and IVa uterine cancer 71
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer 71
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 70
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 69
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer 68
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 67
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial 66
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 65
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup 65
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 64
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma 63
Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy 61
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 60
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 59
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 57
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial 54
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: A multicenter retrospective study 48
Chemotherapy-free treatments: Are we ready for prime time? 47
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) 41
Totale 9.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 0 0 0 0 0 66 19
2021/2022392 32 21 10 23 24 5 11 60 15 24 61 106
2022/2023896 89 104 60 91 70 114 34 70 136 32 54 42
2023/2024762 19 197 51 48 32 108 71 13 23 35 79 86
2024/20251.700 35 40 121 61 97 59 86 74 206 229 378 314
2025/20263.738 548 133 306 502 609 226 595 198 322 291 8 0
Totale 9.065